AN2 Therapeutics (NASDAQ:ANTX) stock is facing a major downturn following the company’s latest update on its EBO-301 Phase 2/3 study.
The company has announced that the Phase 2 study of epetraborole as an optimized background regimen (OBR) in treatment-refractory MAC lung disease achieved its primary endpoint but fell short on a key secondary endpoint.
In addition, AN2 Therapeutics has halted new patient enrollment in the Phase 3 portion of the study due to lower-than-expected efficacy based on blinded aggregate data.
As a result, the company has decided to terminate both the Phase 2 and Phase 3 segments of the study and undergo strategic restructuring to ensure funding through 2027.
AN2 Therapeutics’ Future Outlook
AN2 Therapeutics’ CEO Eric Easom commented, “In the coming months, we will further evaluate the results from the EBO-301 study and make informed decisions regarding potential future development of epetraborole for NTM lung disease in other patient populations.”
ANTX stock has plummeted by 34.8% in Friday morning trading.
Stay tuned for more stock market updates, including the latest on Nauticus Robotics (NASDAQ:KITT) and Iteris (NASDAQ:ITI), as well as the top pre-market movers this morning.
Analyst Insight
It is important to note that the opinions expressed in this article are solely those of the writer and do not reflect any positions held by William White at the time of publication.
Source: Numstocker/Shutterstock.com